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antimalarial treatment  should have an average cure rate of 
;?:95%, as assessed in clinical trials, and that a review-/change- 
of-treatment policy should be initiated when the efficacy of a 
recommended treatment falls to !90% [1]. 
The recent introduction  of genotyping of Plasmodium fal- 
ciparum by polymerase chain reaction (PCR), as a tool to dis- 
tinguish between treatment failure (recrudescence) and new 
infection (reinfection), has significantly improved the assess- 
ment of parasitological cure rates, particularly in antimalarial- 
drug trials conducted in high-transmission areas with extended 
follow-up beyond day 14. However, because of inherent limi- 
tations of the PCR technique and constraints imposed by the 
biology of the parasite [2], PCR-adjusted outcomes should be 
interpreted with caution. 
PCR adjustment to differentiate between recrudescence and 
reinfection is presently achieved by analysis of one or a com- 
bination of highly polymorphic genetic markers—for example, 
   merozoite surface proteins 1 (msp1) and 2 (msp2)—from paired 
blood samples collected at the day of enrollment and the day 
We assessed the influence that consecutive-day blood sam- 
pling, compared with single-day blood sampling, had on 
polymerase chain reaction (PCR)–adjusted parasitological 
cure after stepwise genotyping of merozoite surface proteins 
2 (msp2) and 1 (msp1) in 106 children in Tanzania who had 
uncomplicated falciparum malaria treated with either sul- 
fadoxine-pyrimethamine or artemether-lumefantrine; 78 of 
these children developed recurrent parasitemia during the 
42-day follow-up period. Initial msp2 genotyping identified 
27 and 33 recrudescences by use of single- and consecutive- 
day sampling, respectively; in subsequent msp1 genotyping, 
17 and 21 of these episodes, respectively, were still classified 
as recrudescences; these results indicate a similar sensitivity 
of the standard single-day PCR protocol—that is, 82% (27/ 
33) and 81% (17/21), in both genotyping steps. Interpreta- 
tion  of  PCR-adjusted  results will significantly depend on 
methodology. 
 
 
To ensure effective and life-saving treatment for sick children, 
accurate results from efficacy trials are essential for adequate 
policy decisions on the use of antimalarial drugs in Africa. The 
World Health Organization (WHO)  recommends that a new 
of recurrent parasitemia. However, the use of PCR analysis of 
such paired blood samples in antimalarial-drug trials will not 
reflect the daily dynamics of P. falciparum populations previ- 
ously shown in asymptomatic children in high-transmission 
areas [3]. This observation may also have implications for 
symptomatic P. falciparum infections and needs to be consid- 
ered in clinical-trial protocols, to establish PCR-adjusted par- 
asitological cure. In previous studies of parasite population 
dynamics during the early phase of treatment of travelers re- 
turning  with symptomatic malarial infection, Fa¨rnert et al. 
found  a consistent genotype pattern  during  consecutive-day 
sampling [4], whereas Jafari et al., using a novel quantitative 
method, detected different genotypes at different time points 
[5]. In Gabonese children treated with quinine, the same ge- 
notype pattern  was observed during the infection, although 
alleles disappeared and reappeared over time in some children 
[6]. However, none of these studies applied consecutive-day 
sampling during recurrent parasitemia. 
We report here data from a clinical trial of uncomplicated 
childhood P. falciparum malaria, a trial that was conducted in 
a high-transmission area in Tanzania and that had the primary 
   objective of assessing the influence that consecutive-day blood 
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sampling had on PCR-adjusted parasitological cure rates (PCR- 
APCRs), compared with a standard protocol using paired blood 
samples only. This scientific question was recently identified, 
by WHO, as a research priority [7]. 
Methods.   The study was conducted during April–July 2004 
in Fukayosi, Bagamoyo District, Tanzania, which is located in 
a rural area with holoendemic malaria transmission. The trial 
was conducted in accordance with the Declaration of Helsinki 
and was approved by the ethics committees at the Muhimbili 
University College of Health Sciences (Tanzania) and the Ka- 
rolinska Institutet (Sweden). Informed consent was obtained 
from the parents/guardians of all children enrolled in the study. 
Inclusion criteria included a blood sample positive for P. fal- 
ciparum at a density of 2000–200,000 asexual parasites/mL of 
blood, age ;?:6 months, body weight ;?:6 kg, and either axillary 
temperature ;?:37.5°C or a history of fever during the preceding 
24 h; exclusion criteria included symptoms/signs of severe ma- 
laria, hemoglobin level !50g/L, and any serious underlying dis- 
ease or known allergy to study drugs. 
Enrolled children were assigned randomly to receive a fixed 
combination of either (1) sulfadoxine-pyrimethamine (Fan- 
sidar; Roche) as a single dose under supervision or (2) arte- 
mether-lumefantrine  (Coartem; Novartis), twice daily and on 
the basis of body weight, for 3 days. For logistic reasons, only 
the first of the 2 daily doses of artemether-lumefantrine were 
administered under supervision. 
The duration of outpatient follow-up of the children was 42 
days. Clinical and laboratory assessments were conducted on 
days 0, 1, 2, 3, 7, 14, 21, 28, 35, and 42 or on any day of re- 
current illness. 
Giemsa-stained thick-blood films were examined, quantified 
(in terms of parasites per microliter), and recorded at each 
clinic visit. Quality control was performed according to WHO 
recommendations [7]. 
PCR-APCRs were analyzed by use of stepwise genotyping, 
as described by Mugittu et al. [8]. Initially, all blood samples 
collected at enrollment and during recurrent parasitemia were 
analyzed by use of the msp2 marker, for both assessment of 
parasite-population complexity and establishment of PCR-ad- 
justed cure. In a second step, performed by use of another 
highly polymorphic genetic marker, all children with recurrent 
parasitemia underwent additional genotyping, using the msp1 
marker, to confirm the presence of recrudescences and to assess 
the distribution of PCR outcome. 
All genotyping was performed from dried blood spots on 
filter paper (3MM; Whatman), on the basis of previously de- 
scribed nested-PCR protocols [9]. PCR results for paired blood 
samples collected on  the day of enrollment  and  the day of 
recurrent parasitemia (standard  protocol) were compared, as 
were those for paired blood samples collected on 4 consecutive 
days after enrollment and on 2 consecutive days of recurrent 
parasitemia (enhanced protocol).  For each child, all samples 
were amplified in the same PCR run. The PCR products were 
loaded in parallel on the same gel and were separated by elec- 
trophoresis, for analysis of both the number of genotypes and 
size polymorphism. 
For each step and protocol, recrudescence was defined as the 
presence of at least 1 matching allelic band, and reinfection 
was defined as the absence of any matching allelic band in 
samples collected at enrollment and during recurrent parasi- 
temia. Children with PCR results that, on the basis of either 
the msp2 or msp1 genotyping, fulfilled the reinfection criteria 
were considered to be treatment successes; children with neg- 
ative PCR amplification at enrollment and/or during recurrent 
parasitemia were considered to have nonconclusive PCR out- 
comes. The primary objective was to evaluate the different 
sampling protocols, and the study was considered to be ex- 
ploratory. A sample of 100 children, with a minimum of 50 in 
each treatment arm, was predefined. Data were entered, vali- 
dated, and analyzed by use of SPSS (version 14.0) software. 
Proportions were compared by x2  test, Fisher’s exact test, 
and relative risk (RR), as appropriate. Continuous variables 
were compared by paired-sample t test. Statistical significance 
was defined as P ::: .05. The intention-to-treat  approach was 
used to analyze the primary efficacy outcome in all children 
enrolled. Children lost to follow-up who did not have a defined 
primary efficacy outcome were kept in the analyses until their 
day of exit, after which they no longer contributed to the de- 
nominator in the calculations performed. 
Results.   A total of 434 children were screened for eligibil- 
ity. Of the 175 (40%) who had a blood-slide sample positive 
for P. falciparum, 69 were excluded (61 had a parasite density 
!2000/mL, 4 had severe malaria, 2 lived outside the study area, 
1 left the clinic without notice, and 1 had a severe concomitant 
disease); the remaining 106 children were enrolled, and 56 of 
them were randomly assigned to treatment with sulfadoxine- 
pyrimethamine, 50 to treatment with artemether-lumefantrine. 
Baseline clinical and demographic data showed no significant 
differences between the 2 treatments: in both groups, the geo- 
metric mean parasite count at enrollment was ∼21,600/mL, and 
no deaths occurred. Because 3 of the 56 children treated with 
sulfadoxine-pyrimethamine traveled outside the study area and 
were lost to follow-up (1 each on days 28, 35, and 42 after 
treatment), a total of 103 (97%) of the 106 enrolled children 
were available for analysis of primary efficacy outcome by day 
42 after treatment. 
PCR-based msp2 genotyping of blood samples collected on 
days 1–3 identified 32 additional (i.e., compared with those 
seen at day 0) parasite genotypes in 26 (25%) of the 106 enrolled 
children; of these additional genotypes, 21, 8, and 3 were de- 
tected on days 1, 2, and 3, respectively. When these additional 
32 genotypes were included as part of the initial infection, the 
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proportion of children with multiple genotypes increased from 
60/106 (57%) to 73/106 (69%), although there was no effect 
on the number  of genotypes detected (median, 2 [range, 0– 
7]). Similarly, in 10/78 (13%) children with recurrent parasi- 
temia, a total of 11 parasite genotypes were detected not on 
the initial day but on the following day. When these 11 ge- 
notypes were included as part of the recurrent parasitemia, the 
proportion of children with multiple genotypes increased from 
45/78 (58%) to 48/78 (62%), although there was no effect on 
the number of genotypes detected (median, 2 [range, 0–5]). 
The PCR outcome for the entire cohort, as established by 
stepwise genotyping of msp2 and msp1 for the 2 sampling pro- 
tocols, is presented in figure 1. Of the 33 recrudescences iden- 
tified by the initial msp2 analysis, 6 (18%) were identified 
exclusively by the enhanced protocol with consecutive-day sam- 
pling, meaning that the sensitivity of the standard protocol was 
27/33 (82% [95% confidence interval {CI}, 68%–96%]). When 
PCR results from days 3 and 4 after enrollment were considered, 
only 1 of the 6 additional recrudescences identified exclusively 
by the enhanced protocol was detected. 
After the additional msp1 analysis, 21 episodes were still clas- 
sified as recrudescences (treatment failures); 4 (19%) of these 
21 were so classified on the basis of the enhanced protocol, all 
4 by combining PCR results from the first 2 consecutive days 
after enrollment and from 2 days of recurrent parasitemia; the 
sensitivity of the standard protocol in the second genotyping 
step was therefore 17/21 (81% [95% CI, 63%–99%]). 
When msp1 was used as the initial marker for genotyping, 
the distribution of PCR results in all 78 children with recurrent 
parasitemia was similar to that  when msp2 was used as the 
 
 
 
 
Figure  1.    Flow chart of outcome of polymerase chain reaction (PCR), using stepwise genotyping consisting of initial msp2 genotyping followed by msp1 
genotyping, for the single-day– and consecutive-day–sampling protocols. 
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initial marker: for the paired and consecutive-day samples, re- 
spectively, 26 and 32 episodes were defined as recrudescences, 
46 and 44 as reinfections, and 6 and 2 as nonconclusive PCR 
outcomes. When the 6 episodes initially defined as noncon- 
clusive by the paired-samples protocol were analyzed by the 
enhanced protocol, 3 were classified as recrudescences, 1 as a 
reinfection, and 2 as nonconclusive. 
For the entire cohort, the crude cure rates and PCR-APCRs 
by days 14, 28, and 42 of follow-up, as well as the respective 
analyses using the 2 different genotyping steps and sampling 
protocols, are presented in table 1. 
Discussion.   The results of this clinical trial of uncompli- 
cated childhood malaria, conducted during a highly intensive 
transmission period in Bagamoyo District, Tanzania, indicate 
that a single blood sample may not provide a complete picture 
of all parasite subpopulations present in an individual. The 
similar proportion  of recrudescences that were identified ex- 
clusively by consecutive-day (4+2 days) sampling but were de- 
fined as either reinfections or nonconclusive PCR results when 
the standard single-day (1+1 day) protocol was used in both 
genotyping steps suggests that  PCR protocols  using paired 
blood samples may overestimate the efficacy that antimalarial 
drugs have in high-transmission areas. 
The additional genotypes identified by consecutive-day sam- 
pling but not detectable at the day of enrollment (i.e., not 
detectable by single-day sampling) could be a reflection of either 
 
 
Table  1.    Crude and polymerase chain reaction (PCR)–adjusted cure rates, and relative  risk (RR) for the asso- 
ciation  between  treatment  type and cure  rate,  both after  initial msp2 genotyping  and  after  additional  msp1 
genotyping. 
 
Cure rate, proportion (%) 
 
Treatment 
 
 
Treatment 
 
 
Relative risk, 
Day, protocol
a
 Entire cohort (n p 106) with SP (n p 50) with AL (n p 56) SP vs. AL 
 
Initial msp2 genotyping 
 
14 
PCR unadjusted 97/106 (92) 48/56 (86) 49/50 (98) 1.80 (1.32–2.44) 
PCR-APCR  
Standard 98/106 (92) 49/56 (88) 49/50 (98) 1.75 (1.26–2.43) 
Enhanced 97/106 (92) 48/56 (86) 49/50 (98) 1.80 (1.32–2.44) 
28 
PCR unadjusted 48/105 (46) 24/55 (44) 24/50 (48) 1.09 (0.75–1.57) 
PCR-APCR  
Standard 83/105 (79) 39/55 (71) 44/50 (88) 1.55 (1.10–2.18) 
Enhanced 78/105 (74) 36/55 (66) 42/50 (84) 1.52 (1.08–2.15) 
42 
PCR unadjusted 25/103 (24) 13/53 (24) 12/50 (24) 0.99 (0.64–1.52) 
PCR-APCR  
Standard 76/103 (74) 33/53 (62) 43/50 (86) 1.71 (1.21–2.40) 
Enhanced 70/103 (68) 29/53 (55) 41/50 (82) 1.76 (1.24–2.49) 
Additional msp1 genotyping of recrudescences defined by msp2 genotyping (n p 33) 
 
14 
PCR-APCR 
Standard 
 
99/106 (93) 
 
49/56 (88) 
 
50/50 (100) 
 
2.02 (1.66–2.46) 
Enhanced 98/106 (92) 49/56 (88) 49/50 (98) 1.75 (1.26–2.43) 
28     
PCR-APCR     
Standard 90/105 (86) 41/55 (74) 49/50 (98) 2.05 (1.58–2.67) 
Enhanced 87/105 (83) 40/55 (73) 47/50 (94) 1.81 (1.33–2.46) 
42     
PCR-APCR     
Standard 86/103 (84) 37/53 (70) 49/50 (98) 2.19 (1.67–2.87) 
Enhanced 82/103 (80) 35/53 (66) 47/50 (94) 2.01 (1.48–2.73) 
NOTE.   AL, artemether-lumefantrine; PCR-APCR, PCR-adjusted parasitological cure rate; SP, sulfadoxine-pyrimethamine. 
a  
In the standard protocol, PCR adjustment was performed with paired blood samples collected on the day of enrollment and the 
day of recurrent parasitemia; in the enhanced protocol, PCR adjustment was performed with paired blood samples collected on 4 
consecutive days after enrollment and on 2 consecutive days of recurrent parasitemia. 
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the parasite population  dynamics of P. falciparum [3] or the 
PCR technique’s limitations, which are due to template com- 
petition  in complex infections, in detecting all minority ge- 
notypes that are present [2]. 
The handling and interpretation  of nonconclusive PCR re- 
sults is a dilemma in antimalarial-drug trials, because such 
results can represent either recrudescences or reinfections. 
Thus, an advantage of the enhanced protocol used in the pres- 
ent study was the improved ability to retrieve PCR-adjusted 
outcomes in children for whom paired blood samples showed 
nonconclusive PCR results. 
In the present study, we have used stepwise genotyping of 
2 highly polymorphic loci to distinguish between treatment 
failure and new infection, an approach recently proposed by 
Mugittu et al. [8]. Interestingly, the distribution of PCR-ad- 
justed outcomes was similar when the initial marker used for 
genotyping was either msp2 or msp1. However, when the 2 
markers were combined, the PCR-adjusted outcome changed 
significantly, with a substantial number of recrudescences being 
reclassified as reinfections. This finding is consistent with the 
results reported by Mugittu et al. [8] and indicates that the use 
of a single genetic marker to establish the PCR-adjusted cure 
may result in an underestimation of drug efficacy. On the other 
hand, the increased specificity achieved with incorporation of 
multiple genetic markers into the PCR analysis will simulta- 
neously reduce the sensitivity of detection of true recrudes- 
cences arising from minority clones, which may not be detected 
by all markers, a result that may, instead, underestimate treat- 
ment failure. 
Because a majority of both of the additional genotypes used 
in the present study were detected on the first day after en- 
rollment, and because the additional recrudescences were iden- 
tified by combining PCR results from 2 consecutive days both 
at enrollment and during recurrent parasitemia, we suggest that 
this sampling model (2+2 days) should be the primary target 
for future  studies assessing the efficiency of consecutive-day 
sampling in different endemic settings in Africa. 
In conclusion, the range of possible PCR-APCRs for the 
entire cohort varied from 86% by day 28, when stepwise ge- 
notyping with msp2 and msp1 and the standard paired-samples 
protocol were used, to 68% during an extended follow-up to 
day 42, when a single genetic marker (msp2) and the enhanced 
protocol were used. These results underscore how sensitive the 
assessment of PCR-adjusted cure is to the choice of method- 
ology, and this has critical implications in the interpretation of 
data from in vivo studies, particularly in the context of evi- 
dence-based decisions on new antimalarial-drug policies in 
Africa. 
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